Literature DB >> 11451569

Follistatin-related protein (FSRP): a new member of the follistatin gene family.

A Schneyer1, D Tortoriello, Y Sidis, H Keutmann, T Matsuzaki, W Holmes.   

Abstract

The identification and characterization of follistatin related protein (FSRP) suggests that the follistatin (FS) gene family may actually contain two sub-families. The first includes FS and FSRP by virtue of their high degree of structural homology and comparable activin-binding activity, while the second sub-family contains extracellular matrix proteins that possess one or more 10-cysteine FS domains, but do not bind activin or related TGF-beta family members. Characterization of FSRP indicates that it binds activin with similar affinity and selectivity as FS, but does not bind heparin. Furthermore, although FSRP inhibits activin-mediated gene transcription in heterologous assays, FSRP is much less active than FS in the rat pituitary bioassay. When overexpressed in transgenic mice, FSRP may lead to interruption of follicular development and fertility in females but appears to have only a modest effect on males. These results suggest that FSRP is a structural, but not necessarily a functional homologue of FS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11451569     DOI: 10.1016/s0303-7207(01)00501-9

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  16 in total

1.  Characterization of SMOC-2, a modular extracellular calcium-binding protein.

Authors:  Christian Vannahme; Silke Gösling; Mats Paulsson; Patrik Maurer; Ursula Hartmann
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

2.  Follistatin-like 3 is a mediator of exercise-driven bone formation and strengthening.

Authors:  J Nam; P Perera; R Gordon; Y H Jeong; A D Blazek; D G Kim; B C Tee; Z Sun; T D Eubank; Y Zhao; B Lablebecioglu; S Liu; A Litsky; N L Weisleder; B S Lee; T Butterfield; A L Schneyer; S Agarwal
Journal:  Bone       Date:  2015-04-30       Impact factor: 4.398

Review 3.  Neural induction and early patterning in vertebrates.

Authors:  Mohammad Zeeshan Ozair; Chris Kintner; Ali H Brivanlou
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2012-10-15       Impact factor: 5.814

Review 4.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

Review 5.  Agonists and Antagonists of TGF-β Family Ligands.

Authors:  Chenbei Chang
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-08-01       Impact factor: 10.005

6.  Activin betaA subunit, follistatin and follistatin-like 3 are expressed in the endometrium of ovariectomized rats and regulated by estrogen replacement.

Authors:  Márcia C Ferreira; Inês K D Cavallo; Pasquale Florio; Felice Petraglia; Fernando M Reis
Journal:  J Mol Histol       Date:  2008-09-09       Impact factor: 2.611

Review 7.  The biology of activin: recent advances in structure, regulation and function.

Authors:  Yin Xia; Alan L Schneyer
Journal:  J Endocrinol       Date:  2009-03-09       Impact factor: 4.286

8.  Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto.

Authors:  Paul W Harms; Chenbei Chang
Journal:  Genes Dev       Date:  2003-10-16       Impact factor: 11.361

9.  Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats.

Authors:  Sílvia Busquets; Míriam Toledo; Enrica Marmonti; Marcel Orpí; Eva Capdevila; Angelica Betancourt; Francisco J López-Soriano; Josep M Argilés
Journal:  Oncol Lett       Date:  2011-10-13       Impact factor: 2.967

10.  The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.

Authors:  Robin Stamler; Henry T Keutmann; Yisrael Sidis; Chandramohan Kattamuri; Alan Schneyer; Thomas B Thompson
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.